<it>In vivo </it>antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
<p>Abstract</p> <p>Background</p> <p>An important limiting factor in the development of centrally acting pharmaceuticals is the blood-brain barrier (BBB). Transport of therapeutic peptides through this highly protective physiological barrier remains a challenge for pept...
| Hlavní autoři: | , , , , , , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
BMC
2012-01-01
|
| Edice: | Molecular Brain |
| Témata: | |
| On-line přístup: | http://www.molecularbrain.com/content/5/1/4 |